Validation of the Oxford classification of IgA nephropathy

Slides:



Advertisements
Similar presentations
Supplemental Table A. Baseline proteinuria predicting renal outcome in multivariable Cox-Hazard model PredictorsHR95% CIp value Baseline UPE, g/day
Advertisements

Volume 82, Issue 12, Pages (December 2012)
Improved prognosis of diabetic nephropathy in type 1 diabetes
Volume 81, Issue 2, Pages (January 2012)
Severity of primary MPGN, rather than MPGN type, determines renal survival and post- transplantation recurrence risk  M.A. Little, P. Dupont, E. Campbell,
Volume 70, Issue 10, Pages (November 2006)
Volume 85, Issue 5, Pages (May 2014)
No difference in bleeding risk between subcutaneous enoxaparin and heparin for thromboprophylaxis in end-stage renal disease  Kevin E. Chan, Ravi I. Thadhani,
Histologic classification of glomerular diseases: clinicopathologic correlations, limitations exposed by validation studies, and suggestions for modification 
Volume 92, Issue 4, Pages (October 2017)
Volume 76, Issue 5, Pages (September 2009)
Volume 80, Issue 9, (November 2011)
Volume 93, Issue 1, Pages (January 2018)
Volume 80, Issue 1, Pages (July 2011)
John P. Middleton, Patrick H. Pun  Kidney International 
Volume 87, Issue 5, Pages (May 2015)
Volume 88, Issue 2, Pages (August 2015)
Volume 82, Issue 12, Pages (December 2012)
Volume 86, Issue 4, Pages (October 2014)
The implications of anatomical and functional changes of the aging kidney: with an emphasis on the glomeruli  Richard J. Glassock, Andrew D. Rule  Kidney.
Volume 69, Pages S11-S15 (April 2006)
Volume 79, Issue 12, Pages (June 2011)
C.Y. Hsu, J.D. Ordoñez, G.M. Chertow, D. Fan, C.E. McCulloch, A.S. Go 
Body Mass Index, Coronary Artery Calcification, and Kidney Function Decline in Stage 3 to 5 Chronic Kidney Disease Patients  Jocelyn S. Garland, MD, Rachel.
Serum-soluble urokinase receptor concentration in primary FSGS
Comorbidity and confounding in end-stage renal disease
Volume 81, Issue 3, Pages (February 2012)
Ananda Chapagain, Hamish Dobbie, Michael Sheaff, Muhammad M. Yaqoob 
Volume 82, Issue 3, Pages (August 2012)
A novel classification for IgA nephropathy
Long-term study of mycophenolate mofetil treatment in IgA nephropathy
Volume 79, Issue 9, Pages (May 2011)
Volume 67, Issue 1, Pages (January 2005)
Volume 93, Issue 1, Pages (January 2018)
U-shaped effect of eGFR and mortality
Volume 76, Issue 6, Pages (September 2009)
Volume 82, Issue 3, Pages (August 2012)
Volume 76, Issue 5, Pages (September 2009)
Volume 81, Issue 6, Pages (March 2012)
Volume 76, Issue 3, Pages (August 2009)
Volume 63, Pages S38-S42 (February 2003)
Volume 85, Issue 5, Pages (May 2014)
Methods for guideline development
Environmental exposure to lead and progressive diabetic nephropathy in patients with type II diabetes  J.-L. Lin, D.-T. Lin-Tan, C.-C. Yu, Y.-J. Li, Y.-Y.
Volume 77, Issue 10, Pages (May 2010)
Improved prognosis of diabetic nephropathy in type 1 diabetes
Volume 85, Issue 5, Pages (May 2014)
Volume 73, Issue 8, Pages (April 2008)
Volume 80, Issue 3, Pages (August 2011)
AJKD Atlas of Renal Pathology: IgA Nephropathy
Volume 77, Issue 12, Pages (June 2010)
Volume 74, Issue 9, Pages (November 2008)
Volume 63, Issue 4, Pages (April 2003)
Volume 80, Issue 10, Pages (November 2011)
Michael R. Lattanzio, Matthew R. Weir  Kidney International 
Is it the low-protein diet or simply the salt restriction?
Volume 75, Issue 1, Pages (January 2009)
Volume 74, Issue 3, Pages (August 2008)
Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular.
Volume 63, Pages S13-S16 (February 2003)
Giuseppe Remuzzi, Carlos Chiurchiu, Piero Ruggenenti 
Tobias Breidthardt, Alexandre Mebazaa, Christian E. Mueller 
Membranous nephropathy: recent travels and new roads ahead
Adiponectin: good, bad, or just plain ugly?
Volume 80, Issue 9, Pages (November 2011)
Friends, social networks, and progressive chronic kidney disease
Prediction in idiopathic membranous nephropathy
Volume 60, Issue 2, Pages (August 2001)
Severity of primary MPGN, rather than MPGN type, determines renal survival and post- transplantation recurrence risk  M.A. Little, P. Dupont, E. Campbell,
Volume 86, Issue 2, Pages (August 2014)
Presentation transcript:

Validation of the Oxford classification of IgA nephropathy Andrew M. Herzenberg, Agnes B. Fogo, Heather N. Reich, Stéphan Troyanov, Nuket Bavbek, Alfonso E. Massat, Tracy E. Hunley, Michelle A. Hladunewich, Bruce A. Julian, Fernando C. Fervenza, Daniel C. Cattran  Kidney International  Volume 80, Issue 3, Pages 310-317 (August 2011) DOI: 10.1038/ki.2011.126 Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 1 Frequency of pathological features. Percentage of patients with each pathological feature. The six pathological features illustrated were those with sufficient reproducibility from the Oxford study. Glom, glomeruli. Kidney International 2011 80, 310-317DOI: (10.1038/ki.2011.126) Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 2 Correlations between pathological features and proteinuria at the time of biopsy. Median with interquartile range. *The relationship between proteinuria at the time of biopsy and pathological findings is not seen for either the mesangial score or the tubulointerstitial score for the North American data set, in contrast to the Oxford study. Kidney International 2011 80, 310-317DOI: (10.1038/ki.2011.126) Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 3 Immunosuppressive therapy received during follow-up in relation to pathological features. NA, North America. Kidney International 2011 80, 310-317DOI: (10.1038/ki.2011.126) Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 4 Observed rate of renal-function decline according to predicted quintiles of risk derived from the Oxford multivariate logistic model. In each patient from both cohorts, the predicted probability of a rapid rate of renal-disease progression was calculated based on the β-coefficients from the logistic regression model of the Oxford study. Patients were categorized into quintiles using these predicted probabilities, and the actual observed rate of renal-function decline for each quintile is illustrated with 95% confidence intervals (95% CIs). Kidney International 2011 80, 310-317DOI: (10.1038/ki.2011.126) Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 5 Association between pathological variables and more rapid rate of renal-function decline (defined categorically). Multivariate logistic model using these three pathological features+initial eGFR and follow-up MAP and proteinuria. Adjusted odds ratios are presented with 95% confidence intervals (95% CIs) in reference (ref) to an absent lesion. eGFR, estimated glomerular filtration rate; MAP, mean arterial pressure. Kidney International 2011 80, 310-317DOI: (10.1038/ki.2011.126) Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 6 Interaction between immunosuppression and endocapillary proliferation on the rate of renal-function decline. CI, confidence interval; NA, North America. Kidney International 2011 80, 310-317DOI: (10.1038/ki.2011.126) Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 7 Added value of pathology variables in predicting a more rapid rate of renal-function decline. Pathology variables include the presence of a mesangial score >0.5, the presence of segmental glomerulosclerosis or adhesion, and the severity of tubulointerstitial disease. Clinical variables include eGFR at onset, time-average MAP, and time-average proteinuria. eGFR, estimated glomerular filtration rate; MAP, mean arterial pressure. Kidney International 2011 80, 310-317DOI: (10.1038/ki.2011.126) Copyright © 2011 International Society of Nephrology Terms and Conditions